Welcome to our dedicated page for Ai Technology Group SEC filings (Ticker: AIPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AI Technology Group Inc (AIPG) SEC filings provide detailed information about the company’s corporate actions, acquisitions, and securities issuances. Through current reports on Form 8-K, the Nevada corporation discloses material events such as entering into and completing a Share Exchange Agreement with AVM Biotechnology Inc and Biomed 360 Solutions Corp.
In one Form 8-K, AI Technology Group Inc describes the terms of this share exchange, including the acquisition of 100% of the issued and outstanding shares of AVM, the issuance of common shares of AI Technology Group Inc as consideration, and the resulting status of AVM as a wholly owned subsidiary. The filing also explains that AVM’s outstanding convertible debentures are to be converted into common shares of AI Technology Group Inc and that the shares issued in the transaction are restricted securities issued under exemptions from registration provided by Section 4(a)(2) of the Securities Act of 1933.
A subsequent Form 8-K references a joint press release with AVM Biotechnology Inc and contains extensive forward-looking statements language. It addresses topics such as the proposed acquisition structure, anticipated private financing, regulatory interactions, clinical development plans for AVM’s investigational product candidate, and various risks and uncertainties that could affect outcomes. These filings illustrate how AI Technology Group Inc discusses potential financing transactions, integration considerations, and regulatory factors in its SEC disclosures.
On this page, users can access AI Technology Group Inc’s SEC filings as they are made available from EDGAR, including 8-K reports and other forms when filed. AI-powered tools can help summarize lengthy documents, highlight key sections on acquisitions, unregistered sales of equity securities, and risk disclosures, and make it easier to understand the implications of items such as share exchange terms, convertible debenture conversions, and forward-looking statements in AIPG’s regulatory reports.
AI Technology Group Inc. (AIPG) insider Marcus Johnson filed an initial Form 3 to report his ownership in the company as a director and President. He reports 504,000 shares of common stock held directly and an additional 1,264,234 shares held indirectly through Bellingham Prospects, Inc. The holdings are reported as of the event date of 11/15/2025, giving investors a view of his beneficial ownership position as he serves on the company’s leadership team.
AI Technology Group Inc. filed its quarterly report for the period ended September 30, 2025, showing no revenue and a net loss of $29,628 for the quarter and $33,889 year‑to‑date. Operating costs were primarily professional and listing fees. The company reported a working capital deficit of $75,176, with total current liabilities of $76,165 and no cash on hand.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern and concluded disclosure controls and procedures were not effective due to material weaknesses. Shares outstanding were 1,603,413 as of September 30, 2025. A change in control occurred on July 29, 2025, with new leadership assuming CEO and CFO roles.
Subsequent to quarter‑end, the company issued 27,958,695 restricted common shares to Biomed360 Solutions Corp. shareholders under a definitive agreement, while a contemplated acquisition of AVM Biotechnology remains subject to customary closing conditions. The company also restated certain 2024 balances to correct a material error, reclassifying items to prepaid expenses and equity.
AI Technology Group Inc. (AIPG) filed Amendment No. 1 to a Form 10 to register its common stock under Section 12(g) of the Exchange Act. Once effective, the company will file 10-Ks, 10-Qs and 8-Ks. The filing does not register any securities for sale and specifically excludes the issuance or resale tied to a pending acquisition.
The company is a public shell pursuing a merger with AVM Biotechnology Inc. under a definitive agreement dated August 1, 2025. The deal contemplates AVM becoming a wholly owned subsidiary via share consideration valued at $2.50 per share, repayment of an AVM loan facility of about $2.6 million, and investment tranches including $1.0–$1.5 million at $1.00 per share, four $1.0 million dates at $2.50 per share, and $10–$25 million by closing at $2.50 per share, subject to customary conditions with no assurance of closing.
AIPG reported no revenue and a net loss of $8,374 for 2024, an accumulated deficit of $4,359,105, and a going concern warning from its auditor. Shares outstanding were 1,603,413 as of December 31, 2024. A July 29, 2025 change in control resulted in Bellingham Prospects Inc. holding 78.8%.